Kymera Therapeutics KYMR

HealthcareMarket cap $9B1 connection

Kymera develops targeted protein degraders - drugs that harness the cell's own protein recycling machinery (ubiquitin-proteasome system) to eliminate disease-causing proteins rather than just blocking them. Protein degradation can hit targets that traditional drugs cannot. Pipeline covers immunology and oncology.

Open Kymera Therapeutics's Company Hub Simulate a merger Supply chain See it on the map

Partners 1

Strategic partnerships, joint products and alliances

PfizerHealthcare · $163BSanofi $1.35B deal for Kymera IRAK4 degrader program

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Kymera Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=KYMR" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Kymera Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.